Journal of Cancer Chemotherapy

Dr. Mahmoud K. Singer is a scientist specializing in cancer immunotherapy, translational oncology, and tumor immunology. He serves as a Project Scientist at the University of California, Irvine School of Medicine, where his work focuses on developing new therapies for solid tumors. He earned his Ph.D. in Biochemistry and Immunology from Egypt and has held research positions at the City of Hope National Medical Center, contributing to studies on immune regulation in multiple myeloma and solid tumors. He is a certified in advanced immunoprofiling, with experience spanning preclinical animal studies, clinical immunomonitoring, and translational immunotherapy design. His scientific contributions include more than 30 peer-reviewed publications in leading journals such as Cancers, Cells, Frontiers in Immunology, and Blood, and a U.S. patent application on immune stability modeling. Dr. Singer also serves as a peer reviewer for over 60 international journals.

• Cancer Immunotherapy
• Preclinical and Clinical Research Management
• Molecular and Cellular Immunology
• Vaccine Development (Cancer and Infectious Diseases)
• Translational Cancer Research
• Tumor Microenvironment and Immunometabolism
• Immunophenotyping and Flow Cytometry

• Reviewer Editor, Springer Nature

• Editorial Board Member, European Journal of Preventive Medicine (2024–2027)

• Guest Editor, Journal of Visualized Experiments (JoVE)

• Member of AACR, ASCO, AAI, SITC, and MMRF

• Over 366 verified peer reviews (Publons Top 1%)

• Contributor to NIH, DOD, and CIRM grant-funded immunotherapy projects

1. Singer MK, Assem M, Abdel Ghaffar AB, Morcos NY. Role of TNF-alpha as a survival prognostic marker in chronic lymphocytic leukemia patients. Egypt J Immunol. 2011;18(1):51–60. PMID: 23082480.
2. Singer MK, Assem M, Abdel Ghaffar AB, Morcos NY. Cytokine profiling as a prognostic marker in chronic myeloid leukemia patients. Egypt J Immunol. 2011;18(2):37–46. PMID: 23082469.
3. Shouman A, Leila M, Singer MK, Mahran M, Mohsen M. Vitreous levels of CD4, CD8, and CD28 T-Lymphocytes in proliferative diabetic retinopathy and vitreoretinopathy. WJ Med Sci. 2014; 11(3):364–372.
4. Abdel Hamid F, Singer MK, El-Rouby M, Said M, Tabashy R, El-Houseini M. HepG2 attenuation induced by RNase A modulates immune cell gene profiling and phenotype. J Cancer Res Updates. 2018;7:27–3
5. Abdel Hamid F, Singer MK, et al. Enhancing antigen presentation in human hepatocellular carcinoma using ribonuclease enzyme system. Immunopharmacol Immunotoxicol. 2018;7(1).
6. Dona AA, Caserta E, Singer M, et al. Proteasome inhibition enhances myeloma oncolytic reovirus therapy by suppressing monocytic anti-viral immune responses. Sci Transl Med. 2023 (accepted; medRxiv 2022.03.29.22272857).
7. Zhu Y, Park M, Singer M, et al. CD84 is a therapeutically targetable driver of leukemogenesis via disruption of energy supply in AML. Blood. 2022;140(Suppl 1):89–90.
8. Dona AA, Sanchez JF, Palmer JM, Caserta E, Singer M, et al. Leflunomide confers rapid recovery from COVID-19 with temporal immunologic changes. J Immunol Sci. 2023;7(1):9–27.
9. Zayou L, Prakash S, Singer M, et al. A multi-epitope/CXCL11 mucosal vaccine protects against SARS-CoV-2 infection. J Virol. 2023; e0109623. doi:10.1128/jvi.01096-23.
10. Dhanushkodi NR, Prakash S, Singer M, et al. Anti-viral and anti-inflammatory effect of RAGE-Ig protein against SARS-CoV-2 variants. J Immunol. 2024;212(4):576–585.
11. Prakash S, Dhanushkodi NR, Singer M, et al. Broad-spectrum mRNA/LNP-based pan-coronavirus vaccine induces potent cross-protection. bioRxiv. 2024 Feb. doi:10.1101/2024.02.14.580225.
12. Murtadha M, Park M, Zhu Y, Caserta E, Singer M, et al. Leveraging IFNγ/CD38 regulation to unmask leukemia stem cells in AML. Blood. 2023; blood.2023021570.
13. Dhanushkodi NR, Prakash S, Singer M, et al. Antiviral effector memory TEM and memory B cells mobilized into vaginal mucosa against herpes infection. bioRxiv. 2023; doi:10.1101/2023.05.23.542021.
14. Dhanushkodi NR, Prakash S, Singer M, et al. Mucosal CCL28 chemokine improves protection against genital herpes. J Immunol. 2023;211(1):118–129.
15. Pozhitkov A, Tandoh T, Singer M, et al. Poseidon: Collaborative environment for daratumumab sensitivity research trial. Blood. 2023;142(Suppl 1):7177.
16. Murtadha M, Park M, Zhu Y, Caserta E, Singer M, et al. CD38-directed single-chain T-cell engager targets leukemia stem cells. Blood. 2023;142(Suppl 1):2797.
17. Quadiri A, Prakash S, Singer MK, et al. Therapeutic Prime/Pull vaccination boosts antiviral tissue-resident and effector memory T cells against HSV-2. J Virol. 2024;98(5):e01596-23.
18. Cobb JT, Rawson J, Gonzalez N, Singer MK, Kandeel F, Husseiny MI. Oral Salmonella-based vaccine prevents and reverses type 1 diabetes in mice. Vaccines. 2024;12(3):276.
19. Prakash S, Dhanushkodi NR, Singer MK, et al. Cross-protection induced by conserved coronavirus vaccine epitopes. Front Immunol. 2024;15:1328905.
20. Singer M, Elsayed AM, Husseiny MI. Progress in the development of vaccines for pancreatic adenocarcinoma. Ann Pancreat Disord Treatm. 2024;6(1):001–005.
21. Murtadha M, Park M, Zhu Y, Caserta E, Singer M, et al. A CD38-directed, single-chain T-cell engager targets leukemia stem cells. Blood. 2024;143(16):1599–1615.
22. Tandoh T, Singer M, et al. Single-cell mass cytometry reveals immune-suppressive signature in AL amyloidosis. Amyloid. 2024;31(Suppl):S225.
23. Singer M, Husseiny MI. Immunological considerations for developing effective herpes vaccines. Microorganisms. 2024;12(9):1846. doi:10.3390/microorganisms12091846.
24. Singer M, Elsayed AM, Husseiny MI. Regulatory T-cells: the face-off of the immune balance. Front Biosci (Landmark Ed). 2024;29(11):377. doi:10.31083/j.fbl2911377.
25. Singer M, Zhang Z, Dayyani F, Yaghmai V, Imagawa D, Abi-Jaoudeh N. Modulation of tumor-associated macrophages in HCC microenvironment. Cancers. 2025;17(1):66. doi:10.3390/cancers17010066.
26. Singer M, Zhang Z, Dayyani F, Abi-Jaoudeh N. Cellular immunotherapy for colorectal cancer using dendritic and NK-T cells. Cells. 2025;14(3):166. doi:10.3390/cells14030166.
27. Dona AA, Tandoh T, Nigam L, Singer M, et al. Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma. J Hematol Oncol. 2025;18(1):1. doi:10.1186/s13045-024-01645-3.
28. Singer M, Kandeel F, Husseiny MI. Salmonella-based vaccine: a promising strategy for type 1 diabetes. Vaccines. 2025;13(4):405. doi:10.3390/vaccines13040405.
29. Singer M, Imagawa DK, Alexander M, Abi-Jaoudeh N. The golden hamster: a valuable model for designing cancer therapies. Therapeutics. 2025;2(3):10. doi:10.3390/therapeutics2030010.
30. Singer MK, Moloudizargari M, Sanchez J, Pichiorri F. Dissecting immunophenotypic diversity in multiple myeloma via mass cytometry. Front Immunol. 2025;16:1642609.
31. Singer M, Abi-Jaoudeh N, Lee R. Tumor necrosis-induced expansion of anti-tumor T cells enhances checkpoint inhibitor efficacy. SITC Abstract. 2025; ID:10955.
32. Singer M, Yang C-Y, Chang IY-F, et al. Tumor necrosis-induced expansion of anti-tumor T cells enhances ICI efficacy. J Immunother Cancer (JITC). (Accepted Poster, SITC 2025).
33. Sirota S, Singer M, et al. Global burden of lower respiratory infections and aetiologies, 1990–2023. Lancet. 2025 (under submission).
34. Singer MK. Integrity of data in life sciences: essential for sustaining research progress. (Under submission).
35. Husseiny MI, Singer MK. Long COVID: biological and immunological mechanisms distinguishing post-acute sequelae. (In preparation, MDPI Viruses).